Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02674568
Title Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stemcentrx
Indications

lung small cell carcinoma

Therapies

Rovalpituzumab Tesirine

Age Groups: adult
Covered Countries


No variant requirements are available.